Most Read

Olumiant is marked as the first and only systemic medicine for severe AA adult patients. It is an oral and once-daily JAK inhibitor which is available through specialty

The collaboration will use ImmunoGen’s linker-payload technology which is directed to new targets that are identified by OBT through its OGAP discovery platform. The two companies will jointly

Under the terms of the deal, Bavarian Nordic will be responsible for the supply of 500,000 additional doses of Jynneos vaccines this year. Previously in 2020, the company

Under the deal, Aurigene will receive $8m of upfront licensing payment for rights to the company’s pre-existing programme. The company will also be eligible for up to $60m

The antibody is indicated to treat R/R FL patients who have received at least two prior systemic therapies. Lunsumio is a CD20xCD3 T-cell engaging bispecific antibody that targets

The regulatory approval has been granted for the therapy to treat moderate-to-severe atopic dermatitis in children whose disease is not controlled with topical prescription therapies or when they

The approval will increase MMR vaccine choices in the US. Priorix (Measles, Mumps and Rubella Vaccine, Live) can be given as two doses. It can also be administered

According to a company statement, sugemalimab was approved for use on unresectable stage III NSCLC patients without disease progression after concurrent or sequential platinum-based chemoradiotherapy. NMPA approved sugemalimab

OrbiMed and Maruho have jointly led the financing round, which has also seen participation from HBM Healthcare Investments, Access Biotechnology, TCG X, Omega Funds, Decheng Capital, Samsara BioCapital,